<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093130</url>
  </required_header>
  <id_info>
    <org_study_id>13-001644</org_study_id>
    <nct_id>NCT02093130</nct_id>
  </id_info>
  <brief_title>Study of Pomegranate Juice on Memory in Older Adults</brief_title>
  <official_title>Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to study whether pomegranate juice benefits cognitive abilities in&#xD;
      middle-aged and older non-demented volunteers. Subjects will be randomly assigned to one of&#xD;
      two treatment groups: either a placebo or the pomegranate juice. Subjects will drink eight&#xD;
      ounces of the pomegranate juice or placebo daily for twelve months.&#xD;
&#xD;
      The investigators expect the people receiving the pomegranate juice to show better cognitive&#xD;
      performance compared with those receiving a placebo after one, six, and twelve months. The&#xD;
      investigators believe cognitive decline and treatment response will vary according to a&#xD;
      genetic risk for Alzheimer's.&#xD;
&#xD;
      The investigators will study 212 non-demented subjects aged 50-75 years. Initially, subjects&#xD;
      will undergo a clinical assessment, an MRI and a blood draw to determine genetic risk and to&#xD;
      rule out other neurodegenerative disorders linked to memory complaints.&#xD;
&#xD;
      Subsequently, subjects will undergo the first memory (or neuropsychological) assessments.&#xD;
      Following the first assessment, subjects will begin drinking the juice (either the&#xD;
      pomegranate juice or the placebo). Subjects will undergo a brief memory test at one-month&#xD;
      mark. At six months, subjects will have a second, full neuropsychological assessment. The&#xD;
      final assessment will take place at the end of the study, the 12-month mark. Additional blood&#xD;
      will be drawn at baseline and at 12 months and frozen to assess inflammatory markers if&#xD;
      outcomes are positive.&#xD;
&#xD;
      In total, subjects will be expected to come to the University of California, Los Angeles&#xD;
      (UCLA) for 5 visits during the course of 12-13 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive testing results from Baseline to 1, 6, and 12 months</measure>
    <time_frame>1 year</time_frame>
    <description>Non-demented volunteers aged 50-75 who receive a daily dietary supplement of pomegranate juice will show improved cognitive performance compared to baseline versus those receiving a placebo after one, six, and twelve months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between cognitive change and genotype</measure>
    <time_frame>1 year</time_frame>
    <description>Cognitive change in the pomegranate intervention group will vary according to genotypes found to influence age at dementia onset (e.g., apolipoprotein E [APOE] TOMM40).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Impact of Pomegranate Juice on Memory in Older Adults</condition>
  <arm_group>
    <arm_group_label>Pomegranate Juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight ounces of 100% Pomegranate Juice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate Juice</intervention_name>
    <arm_group_label>Pomegranate Juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement to participate in the 12-month double-blind, placebo-controlled clinical&#xD;
             trial of pomegranate extract.&#xD;
&#xD;
          -  Nondemented subjects either those with normal cognition or with Mild Cognitive&#xD;
             Impairment will be included.&#xD;
&#xD;
          -  Age 50 to 75 years.&#xD;
&#xD;
          -  No significant cerebrovascular disease: modified Ischemic Score of &lt; 4&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
          -  Screening laboratory tests and EKG without significant abnormalities that might&#xD;
             interfere with the study. If screening laboratory tests or EKG show abnormalities,&#xD;
             subject must obtain written clearance from primary care physician before continuing in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular,&#xD;
             Lewy body, frontotemporal) (McKhann et al, 1984). Evidence of other neurological or&#xD;
             physical illness that can produce cognitive deterioration. Volunteers with a history&#xD;
             of stroke, Transient Ischemic Attack (TIA), carotid bruits, or lacunes on MRI scans&#xD;
             will be excluded. Determination of dementia will be based on the clinical evaluation&#xD;
             including assessment of functional abilities, and cognitive screening.&#xD;
&#xD;
          -  Contraindication to the MRI including claustrophobia, metal in body, surgery within 60&#xD;
             days, certain implants or previous abnormal MRI results.&#xD;
&#xD;
          -  Evidence of Parkinson's disease as determined by the motor examination (items 18-31)&#xD;
             of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).&#xD;
&#xD;
          -  History of myocardial infarction within the previous year, or unstable cardiac&#xD;
             disease.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt; 170 or diastolic BP &gt; 100).&#xD;
&#xD;
          -  History of significant liver disease, clinically-significant pulmonary disease, or&#xD;
             diabetes.&#xD;
&#xD;
          -  Current diagnosis of any major psychiatric disorder.&#xD;
&#xD;
          -  Current diagnosis or history of alcoholism or substance addiction.&#xD;
&#xD;
          -  Regular use of any medication that may affect cognitive functioning including:&#xD;
             centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications,&#xD;
             antipsychotics, systemic corticosteroids, medications with significant cholinergic or&#xD;
             anticholinergic effects, anti-convulsants, or Warfarin.&#xD;
&#xD;
          -  Occasional use of anxiety or sleeping medications known to cause cognitive dulling&#xD;
             will be allowed, but discouraged: chloral hydrate, non-benzodiazepine hypnotics such&#xD;
             as: Ambien (Zolpidem) and Lunesta; or benzodiazepines such as Ativan (Lorazepam),&#xD;
             Xanax (Alprazolam), Klonopin (Clonazepam), and Restoril (Temazepam).&#xD;
&#xD;
          -  Use of any of the following medications: Amitriptyline, Amiodarone, Desipramine,&#xD;
             Fenofibrate, Flecainide, Fluconazole, Fluoxetine, Fluvastatin, Fluvoxamine, Isoniazid,&#xD;
             Lovastatin, Ondansetron, Phenylbutazone, Probenecid, Sertraline, Sulfamethoxazole,&#xD;
             Sulfaphenazole, Teniposide, Voriconazole, Warfarin, and Zafirlukast&#xD;
&#xD;
          -  Use of cognitive enhancing supplements (e.g. Ginkgo biloba).&#xD;
&#xD;
          -  Use of any supplement containing pomegranate or pomegranate juice.&#xD;
&#xD;
          -  Use of any investigational drugs within the previous month or longer, depending on&#xD;
             drug half-life.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Longevity Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.semel.ucla.edu/longevity</url>
    <description>UCLA Longevity Center</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Gary Small, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Biobehavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Double-blind Trial</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Pomegranate</keyword>
  <keyword>Memory</keyword>
  <keyword>Memory Impairment</keyword>
  <keyword>Cognition</keyword>
  <keyword>Ages 50-75</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

